VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.4867
+0.0067 (1.40%)
At close: Apr 23, 2025, 4:00 PM
0.4600
-0.0267 (-5.49%)
After-hours: Apr 23, 2025, 4:42 PM EDT
VolitionRx Employees
VolitionRx had 85 employees as of December 31, 2024. The number of employees decreased by 25 or -22.73% compared to the previous year.
Employees
85
Change (1Y)
-25
Growth (1Y)
-22.73%
Revenue / Employee
$14,512
Profits / Employee
-$317,269
Market Cap
46.34M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
VNRX News
- 23 days ago - VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 23 days ago - VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update - PRNewsWire
- 27 days ago - Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025 - PRNewsWire
- 4 weeks ago - Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025 - PRNewsWire
- 4 weeks ago - VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering - PRNewsWire
- 4 weeks ago - VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update - PRNewsWire
- 4 weeks ago - Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry - PRNewsWire
- 5 weeks ago - Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer - PRNewsWire